Category: C.R. Bard
Ferolyn Powell, the former CEO of Evalve who led it to a $410 million acquisition by Abbott, is killed in a motorbike accident in Thailand.
Former Evalve CEO Ferolyn Powell, who led the MitraClip developer to a $410 million acquisition by Abbott (NYSE:ABT), died this month in a motorbike accident in northern Thailand, her family said yesterday.
, Cantel Medical Corp.
, Clayton Dubilier Rice
, InVivo Therapeutics Corp.
, JP Morgan Chase
, NxThera Inc.
, Spectranetics Corp.
, SurModics Inc.
, Urologix Inc.
, Abbott Laboratories
Here's a look at some of the top legal news stories for medical device companies this week: Ex-sales rep sues Medtronic, claims she was fired for blowing the whistle; J&J's Ethicon settles Prolift pelvic mesh bellwether; Appeals court upholds AngioDynamics injunction, $160m penalty against Biolitec; Bard's Medafor wins injunction against CryoLife's PerClot Topical
A federal judge grants C.R. Bard's Medafor division's bid for an injunction barring U.S. sales of CryoLife's PerClot Topical hemostasis powder.
C. R. Bard is reportedly close to settling a suit filed in a West Virginia federal court by a woman who claimed she was injured by the company's pelvic-mesh device, Avaulta Plus.
C.R. Bard (NYSE:BCR) is reportedly close to settling a suit filed in West Virginia federal court by a woman who claimed she was injured by the company's pelvic-mesh device, Avaulta Plus.
C.R. Bard inks a deal for Boston Scientific to distribute its Lutonix drug-eluting balloon in the U.S.
The federal judge overseeing some 70,000 pelvic mesh product liability lawsuits urges the plaintiffs and the medical device company defendants to settle.
(Reuters) — A U.S. judge Thursday urged transvaginal mesh device makers and the women suing them to work harder to resolve their 10s of thousands of lawsuits in 1 of the biggest U.S. mass torts in history.
C. R. Bard reports a lower fourth-quarter profit, due largely to hefty gains recorded for a patent infringement suit against W.L. Gore & Associates and the sale of its electrophysiology unit in 2013.
A tough comparison with the year-ago quarter pushed C.R. Bard's (NYSE:BCR) 4th-quarter profits down 80%, due largely to hefty gains from patent infringement suit and the 2013 sale of its electrophysiology unit.